Home > IP News
Final Verdict Could Impact Future Research and Funding
The U.S. Court of Appeals for the Federal Court recently heard oral arguments in the continuing battle between the UC Berkeley and the Broad Institute over who gets to claim the patents, the money, and the legacy of the CRISPR-Cas9 gene-editing technology. At the heart of the matter is the nebulous concept of the obviousness of invention and what constitutes a reasonable
expectation of success.
CRISPR-Cas9 is a gene-editing technique adapted from a self-defense mechanism in prokaryotic cells which disables foreign genetic material. The technique was first described in a 2012 Science paper by Jennifer Doudna, Ph.D., of the UC Berkeley and Emmanuelle Charpentier, Ph.D., then of Umeå University in Sweden, now at the Max Planck Institute in Berlin.